Help us create better treatments forEssential Tremor

An oral treatment that may improve day-to-day functioning for people with Essential Tremors is being evaluated. With your participation, we can complete this breakthrough research.
Get Started Today

See If You Can Join

To see if you may be eligible to participate in this Essential Tremor Study, please complete our brief online questionnaire.
All health-related information you provide will remain completely confidential and will only be used to determine if you may be eligible to participate.

Essential Tremor Research

Essential tremor is a neurological condition that causes a rhythmic trembling of the hands, head, voice, legs, or trunk. It is often confused with Parkinson’s disease although essential tremor is eight times more common, affecting an estimated 7 to 10 million Americans and millions more worldwide.


There have been limited treatments to help slow Essential Tremor progression. We’re spreading the news that we're working on a new option to treat the disease.

About the Study
This is a phase 2b clinical study evaluating the investigational medication suvecaltamide (JZP385) for the treatment of adult patients with moderate to severe essential tremor. The purpose of this study is to learn more about the safety and tolerability of the study medication, as well as to evaluate whether the study medication will improve disability associated with tremor.
Who Can Participate?
The study is enrolling people (age 18-80 years) who have been diagnosed with ET according to the Movement Disorder Society Consensus Statement on the Classification of Tremors from the Task Force on Tremor of the International Parkinson’s and Movement Disorder Society. Patients must also have moderate to severe disability associated with their tremor as defined by the Tremor Research Group Essential Tremor Rating Scale [TETRAS] and clinician’s assessment.

Why Is This Study Important

There has not been an approved medication for the treatment of Essential Tremors in over 50 years and there has never been a medication developed specifically to treat this condition.

If you decide to join this study, your health and safety will carefully be monitored by specialists, and your participation will help doctors evaluate the study drug to measure its efficacy and safety.

Why you should participate

Potential to have access to a study drug that may decrease tremor severity.
Close care and monitoring from Essential Tremor specialists.
The opportunity to help advance the treatment of Essential Tremor disease.
Reimbursement for study-related travel expenses.

Your health and safety is our priority

Please answer the questions below to see if you may be eligible for this study
Completing this questionnaire does not obligate you to participate in the study. Your answers will help determine if you may be eligible. If your answers indicate you may be eligible, you will have the opportunity to contact a clinic site near you to learn more about the study.
Take the 60-second Questionnaire

How does it work

1
Take the 60-second questionnaire
Complete our sign up form, our platform is secure and we will only use your information to match you to a Clinical Trial.
2
Get Screened
Within 24 hours, a clinic representative will contact you at your preferred time and channel to ask a few questions to see if you're eligible for the study. Feel free to ask the representative any questions you have about your symptoms, eligibility, the study treatment, etc.
3
Enroll in the Clinical Trial
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Clinical research site locations near you

SC3 Research Group, Inc - Pasadena

Phone: (626) 250-2070

Address: 50 BELLEFONTAINE ST., STE 203, PASADENA, CA 91105

SC3 Research Group, Inc - Beverly Grove

Phone: (323) 446-6905

Address: 6363 WILSHIRE BLVD., SUITE 516, LOS ANGELES, CA, 90048

Make a difference. Participate in Research

Your health and safety is our priority